| Form | Liquid |
|---|
| Host Species | Mouse |
|---|
| Clonality | Monoclonal |
|---|
| Isotype | IgG1-kappa |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Concentration | 1mg/ml |
|---|
| Endotoxin Level | Please contact the lab for this information. |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Species Reactivity | Human |
|---|
| Target | 5T4, TPBG, WAIF1, M6P1, 5T4 oncofetal trophoblast glycoprotein, Trophoblast glycoprotein, 5T4 oncofetal antigen, 5T4 oncotrophoblast glycoprotein, Wnt-activated inhibitory factor 1 |
|---|
| Storage Buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Expression System | Mammalian Cells |
|---|
| Accession Number | Q13641 |
|---|
| Background | Naptumomab is a fusion protein of a tumor-targeting superantigen (TTS). Naptumomab stimulates the immune system to recognize and kill tumor cells and can be used in the study of refractory solid tumors such as renal cell carcinoma.<br>• 5T4 oncofoetal antigen: an attractive target for immune intervention in cancer., PMID:27757559<br/>• ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models., PMID:34045226<br/>• Structural insights into the inhibition of Wnt signaling by cancer antigen 5T4/Wnt-activated inhibitory factor 1., PMID:24582434<br/>• Understanding and exploiting 5T4 oncofoetal glycoprotein expression., PMID:25066861<br/>• 5T4 oncotrophoblast glycoprotein: janus molecule in life and a novel potential target against tumors., PMID:17484803<br/>• Immunohistochemical Detection of 5T4 in Renal Cell Carcinoma., PMID:36735485<br/>• Role of TPBG (Trophoblast Glycoprotein) Antigen in Human Pericyte Migratory and Angiogenic Activity., PMID:31018661<br/>• TroVax in colorectal cancer., PMID:25483641<br/>• Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer., PMID:22409460<br/>• 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy., PMID:20088718<br/> |
|---|
| Alternative Names | ABR-217620, ANYARA, TTSCD3, 676258-98-3 |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|